HomeCompareCYT vs EPRT

CYT vs EPRT: Dividend Comparison 2026

CYT yields 66.23% · EPRT yields 3.97%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CYT wins by $815.7K in total portfolio value
10 years
CYT
CYT
● Live price
66.23%
Share price
$3.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$880.0K
Annual income
$221,634.45
Full CYT calculator →
EPRT
EPRT
● Live price
3.97%
Share price
$30.36
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$64.3K
Annual income
$13,170.85
Full EPRT calculator →

Portfolio growth — CYT vs EPRT

📍 CYT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCYTEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CYT + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CYT pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CYT
Annual income on $10K today (after 15% tax)
$5,629.14/yr
After 10yr DRIP, annual income (after tax)
$188,389.28/yr
EPRT
Annual income on $10K today (after 15% tax)
$337.37/yr
After 10yr DRIP, annual income (after tax)
$11,195.22/yr
At 15% tax rate, CYT beats the other by $177,194.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CYT + EPRT for your $10,000?

CYT: 50%EPRT: 50%
100% EPRT50/50100% CYT
Portfolio after 10yr
$472.2K
Annual income
$117,402.65/yr
Blended yield
24.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CYT
Analyst Ratings
2
Buy
1
Hold
2
Sell
Consensus: Buy
Price Target
$2.00
-33.8% upside vs current
Range: $2.00 — $2.00
Altman Z
9.4
Piotroski
1/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+16.9% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CYT buys
0
EPRT buys
0
No recent congressional trades found for CYT or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCYTEPRT
Forward yield66.23%3.97%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$880.0K$64.3K
Annual income after 10y$221,634.45$13,170.85
Total dividends collected$742.8K$38.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy
Analyst price target$2.00$35.50

Year-by-year: CYT vs EPRT ($10,000, DRIP)

YearCYT PortfolioCYT Income/yrEPRT PortfolioEPRT Income/yrGap
1← crossover$17,323$6,622.52$11,212$512.01+$6.1KCYT
2$29,256$10,721.37$12,689$692.09+$16.6KCYT
3$48,227$16,923.00$14,521$944.30+$33.7KCYT
4$77,675$26,071.48$16,841$1,302.88+$60.8KCYT
5$122,356$39,243.54$19,841$1,821.64+$102.5KCYT
6$188,694$57,773.40$23,818$2,587.47+$164.9KCYT
7$285,170$83,268.01$29,230$3,744.65+$255.9KCYT
8$422,742$117,609.16$36,816$5,540.38+$385.9KCYT
9$615,273$162,940.02$47,806$8,413.17+$567.5KCYT
10$879,977$221,634.45$64,324$13,170.85+$815.7KCYT

CYT vs EPRT: Complete Analysis 2026

CYTStock

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company is also developing CYT-1853, which is in preclinical trials for solid tumors and hematologic malignancies. The company was incorporated in 2012 and is based in Lexington, Massachusetts.

Full CYT Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CYT vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CYT vs SCHDCYT vs JEPICYT vs OCYT vs KOCYT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.